The Global Innovation Forum
In a significant departure from most traditional conferences, TGIF, Feb 16th-18th, 2018 was a highly interactive platform for ‘C-suit’ executives, directors, presidents and decision-makers from diverse industries (e. g. Life science, IT, semiconductor, nanotech, energy) and geographies which:
- Showcased individual and unified expertise in overcoming issues across the spectrum of discovery, development, commercialization and patient care in oncology.
- Highlighted recent cancer related advances and breakthroughs.
- Engaged decision makers from over 200 prestigious institutions and companies from India and abroad to create new opportunities for value creation.
A majority of the time at the forum was spent in active discussions through well-crafted panels and round table sessions that outlined specific multi-dimensional initiatives. Each initiative required active participation in the design and discussion phase at the forum; and future involvement in making products and services available for execution of the projects outlined. With the push for developing novel diagnostics and therapies, the need for translational medicine has increased exponentially. Genomic and proteomic technologies have generated critical information that are advancing the integration of biology and IT into translational medicine (BioIT), development of artificial intelligence based diagnostic and treatment models, among others. But, in order to develop clinically relevant therapeutic agents from translational research; access to the infrastructure, integration of national health data and collaboration among researchers, clinicians and pharmaceutical companies to conduct clinical trials are paramount. The discussion panels at the TGIF 2018 forum were designed to better understand the gaps and formulated a strategy that would invigorate cancer care in India. The discussions at the forum focused on the following:
- Role of government(s) in supporting translational oncology in India. The process involved in the integration of translational cancer research between non-government organizations and the government. An active discussion on how to coordinate efforts in the establishment of a consortia in India with an active involution from government(s), academia and industry.
- Designing clinical cancer research programs, role of informatics and participation on a global scale. Setting up global scale collaborative and cooperative clinical trials. Also assist in effectuating long-term collaborations that would serve countries with limited resources to further develop their potential for cancer research and treatment.
- Future of diagnostics and individualized therapy. The potential for integration of different “omics” in developing effective diagnostics and tailoring therapeutic approaches in cancer treatment. One such topic discussed in depth; would be the origin of Chimeric Antigen Receptor T-cell therapy and its potential in the future.
Press Releases
Video Gallery
Playlist
10 Videos
Dr Desaiah Durisala, PhD, FmrAdvisor, Strategy, Global Scientific Communications, Eli Lilly and com
7:32
Dr Edus Houston Warren, MD, PhD Director, Global Oncology, Fred Hutchinson Cancer Institute, Seat
3:23
Dr Pallu Reddana, PhD Dean in charge, School of Lifesciences, University of Hyderabad, Hyderabad,
7:39
Dr Purvish Parikh, MD Director, Precision Oncology and Research, Asian Institute of Oncology, Som
4:27
Dr Somasundaram Subramanian, MD Surgical Oncologist & Cancer Survivor, Founder & CEO, Eurasian Fe
7:38
Dr Praveen Arany, D D S , Ph D, Assistant Professor, Oral Biology & Biomedical Engineering, School
5:28
Testimonals
We should complement the Govt of AP, Chief minister Sri Nara Chandra Babu Naidu has really given a new focus and thrust to research and innovation. Priority areas like prevention, prophylaxis, health education should be the crucial areas in cancer care
I am really enjoying being at the conference and it is for better than what I expected. It is not just a scientific conference but a socio-politico-economic and scientific leaders meeting. The delegates in the conference from India and abroad are really the “leaders".
This conference has been fun, interesting and different from various cancer conferences I attend in the USA. It is interesting on how the leaders from different sectors have come together and this will open new avenues to collaboration and building an ecosystem.
Elixsys platform is an excellent model for doing two things- one to bring all the intellectuals together and initiate collaboration and immediately brings the government to provide funding or regulatory easing
With recent advances if we can detect cancer we could be arriving at screening techniques which can detect cancer at early stages that can be a breakthrough. With the rise in seed funding for many academic scientists and increase in the number of incubators encourages innovation in research.
The conference is unique in many ways where it has brought academicians and investors in the same room. Based on my own personal research it is a great forum to try and find the right partners and am very excited about meeting and interacting with people.
Translational research is the next big wave in USA and you are the early surfers in Vizag.
I must congratulate the organisers and particularly I am so impressed by Dr. Himabindu for bringing all the visionary people under one roof to discuss about innovation. I have attend- ed many large conferences where people interact with only the people they know but, in this conference, whosoever attended had actively participated and are highly focussed. Whatever Dr. Himabindu has done in a year and half is truly amazing!
This is the first conference I have seen in last 12 years that is very focused on one single area, oncology and innovation, which is number one killer in Japan, number two in USA and it is a big problem. I would like to thank Himabindu garu & team for organizing this confer- ence where I have first seen that level of intellectual stimulating conference. VCR park is the greatest idea and much needed particularly for cancer. By having lot of business develop- ment expertise and an efficient business model VCR park can be successful.
The objective and scientific content of the conference made me believe that it is very exciting and novel platform. It brings several stakeholders from start-ups, seed funders, translational researchers, experts in intellectual property and several oncologists under one roof. The roundtable discussions were extremely productive. The upcoming bio- cluster will serve a very important unmet need and “Elixsys platform” would serve as a valuable tool in facilitating the unmet needs on collaboration.
I thank Dr. Himabindu on bringing together the stakeholders working in cancer biology and connecting the scientists in India with the global. The vision of Dr. Himabindu and how she identified the strengths in the country regarding hospitals, academia, research institutes and the industry is what attracted me to the conference. Bringing all of them on a single platform to discuss and take initiatives is remarkable. As Dean-in-Charge, School of Life sci- ences for University of Hyderabad and as a member of Federation of Asian Biotech Associa- tions (FABA) we would support this vision and help in setting up the VCR Park.
cure